Literature DB >> 2158836

Comparison of the effects of xamoterol and isoprenaline on rat cardiac beta-adrenoceptors: studies of function and regulation.

M T Kowalski1, D Haworth, X Lu, D S Thomson, D B Barnett.   

Abstract

1. The effects of the beta 1-selective partial agonist xamoterol and the full agonist isoprenaline on rat cardiac beta-adrenoceptors were compared in functional studies of heart rate response in vivo and in vitro. In addition, the ability of both agents to cause receptor down-regulation in the rat heart following chronic (6 days) subcutaneous infusions was assessed by radioligand binding with [125I]-pindolol. 2. In the functional studies, xamoterol produced a maximal effect equivalent to approximately 65% of that of isoprenaline and was overall less potent than the full agonist. 3. Compared to saline control, the density of beta-adrenoceptors was reduced approximately 39% in ventricular membranes prepared from animals after 6 days of isoprenaline infusion but was unaffected by xamoterol. The relative proportions of the beta-adrenoceptor subtypes were unchanged by either active treatment. 4. Plasma xamoterol level at the end of the infusion period was equivalent to that associated with maximum tachycardia in vivo and to the concentration producing maximal stimulation of the rat isolated atrium in vitro. Thus suggesting 100% beta-adrenoceptor occupancy during the period of xamoterol infusion. 5. These results indicate that in this animal model xamoterol does not induce cardiac beta-adrenoceptor down-regulation during chronic treatment, with doses that produce a maximal functional response both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158836      PMCID: PMC1917501          DOI: 10.1111/j.1476-5381.1990.tb14648.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Beta-adrenergic receptor subtypes: properties, distribution, and regulation.

Authors:  K P Minneman; R N Pittman; P B Molinoff
Journal:  Annu Rev Neurosci       Date:  1981       Impact factor: 12.449

3.  Myocardial beta-adrenergic receptor downregulation in heart failure.

Authors:  M R Bristow
Journal:  Int J Cardiol       Date:  1984-05       Impact factor: 4.164

4.  Endogenous noradrenaline masks beta-adrenergic receptors in rat heart membranes via tight agonist binding.

Authors:  V Nerme; Y Severne; T Abrahamsson; G Vauquelin
Journal:  Biochem Pharmacol       Date:  1985-08-15       Impact factor: 5.858

5.  (-)-[125I]pindolol binding to the human platelet beta-adrenoceptor: characterisation and agonist interactions.

Authors:  N Cook; S R Nahorski; D B Barnett
Journal:  Eur J Pharmacol       Date:  1985-07-17       Impact factor: 4.432

6.  The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

Authors:  A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

7.  Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.

Authors:  W S Colucci; R W Alexander; G H Williams; R E Rude; B L Holman; M A Konstam; J Wynne; G H Mudge; E Braunwald
Journal:  N Engl J Med       Date:  1981-07-23       Impact factor: 91.245

8.  (-)-[125I]-iodopindolol, a new highly selective radioiodinated beta-adrenergic receptor antagonist: measurement of beta-receptors on intact rat astrocytoma cells.

Authors:  K Barovsky; G Brooker
Journal:  J Cyclic Nucleotide Res       Date:  1980

9.  Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol.

Authors:  R D Aarons; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

10.  Distribution and function of beta-adrenoceptors in different chambers of the canine heart.

Authors:  S P Baker; H M Boyd; L T Potter
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

View more
  4 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Role of AKAP79/150 protein in β1-adrenergic receptor trafficking and signaling in mammalian cells.

Authors:  Xin Li; Mohammed M Nooh; Suleiman W Bahouth
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

Review 3.  Beta receptor antagonists in the treatment of heart failure.

Authors:  H Persson; L Erhardt
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

4.  The effect of orthotopic transplantation on total, beta 1- and beta 2-adrenoceptors in the human heart.

Authors:  M R Chester; B Madden; D Barnett; M Yacoub
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.